Oxygen
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Oxygen: From Unspecified Original Indication to Dry Eye Syndrome
One-Sentence Summary
Oxygen (DrugBank DB09140) has no original indication or mechanism-of-action data currently available in this evidence pack. The TxGNN model predicts a possible association with Dry Eye Syndrome, but this rests solely on a knowledge-graph prediction score (93.22%) — there are no supporting clinical trials and no supporting publications, and the evidence pack’s own mechanistic assessment finds no direct physiological rationale for the link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no original indication is recorded in the evidence pack |
| Predicted New Indication | Dry Eye Syndrome |
| TxGNN Prediction Score | 93.22% |
| Evidence Level | L5 |
| Denmark Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Oxygen is not currently available in this evidence pack, and no original approved indication is on record either, so a mechanistic comparison between the original and predicted indications cannot be made.
The TxGNN-generated rationale for this candidate explicitly states that there is no direct physiological mechanism supporting systemic or topical oxygen therapy for dry eye syndrome. The proposed link — between oxygen and tear film stability or corneal epithelial repair — is described only as an indirect hypothesis (the “oxidative stress hypothesis”), without any supporting mechanistic literature.
Given the combination of missing original-indication/MOA data and the evidence pack’s own assessment that the mechanistic link is speculative, this prediction should be treated as a low-confidence signal from the knowledge graph rather than a pharmacologically grounded hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Denmark Market Information
Oxygen currently holds no marketing authorisations in Denmark (market status: Not Marketed; 0 authorisations on record).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trial or literature evidence exists for oxygen in dry eye syndrome, mechanism-of-action data is unavailable, and the evidence pack’s own mechanistic review found no plausible physiological link between oxygen therapy and dry eye syndrome. Oxygen also has no marketing authorisation in Denmark, so there is currently no regulatory or commercial pathway to act on.
To proceed, the following is needed:
- TFDA/SmPC label warnings and contraindications (currently a Blocking data gap — required before any safety pre-assessment)
- Mechanism of action (MOA) data for Oxygen
- Original approved indication history
- Preclinical or mechanistic studies specifically evaluating oxygen therapy in dry eye disease
- Confirmation of Denmark/EU marketing authorisation status if commercial availability is later considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.